Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension

International Journal of Cardiology

Volumn 115, Issue 1, 2007, Pages 67-72

  Braun, S ^a   Schrotter H ^a   Schmeisser, A ^a   Strasser, R H ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Inhaled iloprost; Pulmonary venous hypertension; Reversibility testing

Indexed keywords

GLYCERYL TRINITRATE; ILOPROST; OXYGEN;

ADULT; AGED; ARTERIAL OXYGEN SATURATION; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FACIAL FLUSHING; FEMALE; HEART CATHETERIZATION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART TRANSPLANTATION; HUMAN; INTERMETHOD COMPARISON; LUNG BLOOD VESSEL; LUNG EDEMA; LUNG VASCULAR RESISTANCE; MALE; MONOTHERAPY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS OXYGEN TENSION;

ADMINISTRATION, INHALATION; ADULT; AGED; FEMALE; HEART CATHETERIZATION; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; MIDDLE AGED; NITROGLYCERIN; OXYGEN INHALATION THERAPY; PILOT PROJECTS; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 33845210875     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.01.067     Document Type: Article

References (32)

1. Drazner M., Hamilton M., Fonarow G., Creaser J., Flavell C., and Stevenson L. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 18 (1999) 1126-1132
2. Morares D.L., Colucci W.S., and Givertz M. Secondary pulmonary hypertension in chronic heart failure. Circulation 102 (2000) 1718-1723
3. Budhiraja R., Tuder R., and Hassoun P. Endothelial dysfunction in pulmonary hypertension. Circulation 109 (2004) 159-165
4. West J., and Costello O. Vulnerability of pulmonary capillaries in heart disease. Circulation 92 (1995) 622-631
5. Anguita M., Arizon J.M., Valles F., et al. Influence on survival after heart transplantation of contraindications seen in transplant recipients. J Heart Lung Transplant 11 (1992) 708-715
6. Kirklin J.K., Nafeh D.C., McGiffin, McVay R.F., Blackstone E.H., and Karp R.B. Analysis of morbid events and risk factors for death after cardiac transplantation. J Am Coll Cardiol 11 (1988) 917-924
7. Zales V.R., Pahl E., Backer C.L., Crawford S., Mavroudis C., and Benson W. Pharmacologic reduction of pretransplantation pulmonary vascular resistance predicts outcome after pediatric heart transplantation. J Heart Lung Transplant 12 (1993) 965-973
8. Hosenpud J., Bennett L., Keck B., Boucek M., and Novick R. The registry of the international society for heart and lung transplantation: seventeenth official report-2000. J Heart Lung Transplant 19 (2000) 909-930
9. Natale M.E., and Pina I. Evaluation of pulmonary hypertension in heart transplant candidates. Curr Opin Cardiol 18 (2003) 136-140
10. Stobierska-Dzierzek B., Awad H., and Michler R. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 38 (2001) 923-931
11. Costard-Jäckle A., and Fowler M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 19 (1992) 48-54
12. Klotz S., Deng M.C., Hanafy D., et al. Reversible pulmonary hypertension in heart transplant candidates-pretransplant evaluation and outcome after orthotopic heart transplantation. Eur J Heart Fail 5 (2003) 645-653
13. Bhatia S., Kirshenbaum J., Shemin R., et al. Time course of resolution of pulmonary hypertension and right ventricular remodelling after orthotopic cardiac transplantation. Circulation 76 (1987) 819-826
14. Chau E., Bailey K., Mahoney D., et al. Predictors of reversibility of pulmonary hypertension in cardiac transplant recipients in the first postoperative year. Circulation 94 Suppl. II (1996) 267-272
15. Auler J., Carmona M., Bocchi E., et al. Low doses of inhaled nitric oxide in heart transplant recipients. J Heart Lung Transplant 15 (1996) 443-450
16. Kieler-Jensen N., Lundin S., and Ricksten S. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside. J Heart Lung Transplant 14 (1995) 436-443
17. Erickson K.W., Costanzo-Nordin M.R., O'Sullivan J., et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Lung Transplant 9 (1990) 526-537
18. Murali S., Uretsky B., Armitage J., et al. Utility of prostaglandin E1 in the pretansplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant 11 (1992) 716-723
19. Murali S., Uretsky B.F., Reddy S., Tokarczyk T.R., and Betschart A.R. Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: comparative effects of various pharmacologic agents. Am Heart J 122 (1991) 1375-1381
20. Haraldson A., Kieler-Jensen N., Nathorst-Westfelt U., Bergh C., and Ricksten S. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. CHEST 114 (1998) 780-786
21. Pamboukian S., Carere R., Webb J., et al. The use of milrinone in pretransplant assessment of patients with congestive heart failure and pulmonary hypertension. J Heart Lung Transplant 18 (1999) .367-371
22. Kieler-Jensen N., Ricksten S., Stenquist O., et al. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 13 (1994) .366-375
23. Brooks H., Kirk E., Vokonas P., Urschel C., and Sonnenblick E. Performance of the right ventricle under stress: relation to right coronary flow. J Clin Invest 50 (1971) .2176-2183
24. De Wet C., Affleck D.G., Jakobsohn E., et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 127 (2004) .1058-1067
25. Hoeper M., Olschewski H., Ghofrani H., et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. J Am Coll Cardiol 35 (2000) .176-182
26. Grant S.M., and Goa K.L. Iloprost: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischemia and extracorporal circulation procedures. Drugs 43 6 (1992) 889-924
27. Olschewski H., Simonneau G., Gaile N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 43 6 (2002) 322-329
28. Sablotzki A., Hentschel T., Gruenig E., et al. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg 22 (2002) 746-752
29. Olschewski H., Rhode B., Behr J., et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. CHEST 124 (2003) 1294-1304
30. Schermuly R., Schulz A., Ghofrani H., et al. Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. J Pharmacol Exp Ther 303 (2002) 741-745
31. Goldsmith D.R., and Wagstaff A.J. Inhaled iloprost. Drugs 64 (2004) 763-773
32. Griffiths M.J., and Evans T.W. Inhaled nitric oxide therapy in adults. N Engl J Med 353 (2005) 2683-2695